Warburg Pincus and ArchiMed Invest in Polyplus-transfection

ARCHIMED Acquires Majority Stake in ExcellGene and Magellan Biologics

September 25, 2025

Biotechnology

ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Switzerland-based ExcellGene SA and its sister company Magellan Biologics & Consulting (Portugal), partnering with founders Florian and Maria Wurm and management. The investment creates a group focused on cell line development, gene transfer and cell culture-based manufacturing to accelerate work on biosimilars, recombinant proteins and transfection/media products.

Sartorius Stedim Biotech Acquires Polyplus

April 13, 2023

Biotechnology

Sartorius Stedim Biotech agreed to acquire Strasbourg-based Polyplus (Polyplus‑transfection S.A.) for €2.4 billion, pending customary regulatory approvals. The transaction buys the business from private equity backers including ARCHIMED and Warburg Pincus and strengthens Sartorius’s cell & gene therapy reagent and upstream bioprocessing portfolio.

ARCHIMED Invests in PlasmidFactory

October 7, 2022

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED (via its MED Platform II fund) has invested in PlasmidFactory, a Bielefeld, Germany-based contract manufacturer of plasmid and minicircle DNA used in gene and cell therapies. The founder and management will remain in place with a roll-over of a portion of proceeds; proceeds will fund rapid expansion including construction of a larger GMP-compliant production facility to meet growing demand.

ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)

November 3, 2021

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.

ARCHIMED Acquires Majority Stake in Xpress Biologics

October 5, 2021

Biotechnology

ARCHIMED has acquired a majority stake in Liège-based Xpress Biologics and will finance a ten-fold expansion of the company's plasmid DNA production capacity with the implementation of GMP services. Founders Christian Rodriguez, Philippe Ledent and Marc Daukandt, together with public investor Noshaq, will reinvest proceeds; ARCHIMED is investing via its MED II fund to help internationalize distribution into the US and Asia‑Pacific.

Warburg Pincus Acquires Pregis from Olympus Partners

June 5, 2019

Packaging

Warburg Pincus has agreed to acquire Pregis LLC, a leading manufacturer of protective packaging materials and automated systems, from Olympus Partners for an undisclosed amount. Pregis will continue to be led by CEO Kevin Baudhuin as Warburg Pincus partners with management to accelerate growth, expand capabilities in e-commerce enablement and automation, and build on recent European expansion.